Artios Pharma
Executivos
Veja o organograma con seus 23 executivos principais
Biografias mais buscadas da Artios Pharma
- Niall Martin, Chief Executive Officer and Director
- Raphael Wisniewski, Director
- Samantha Truex, Director
Recentes movimentos de executivos em Artios Pharma
- Chris Liu, ingressou na Companhia como Director (Notícia publicada em 12 de abril de 2024).
- Christine Silverstein, ingressou na Companhia como Chief Financial Officer (Notícia publicada em 8 de fevereiro de 2024).
Criar um alerta
para seguir os movimentos de executivos da Artios Pharma.
Farmacêutica
Artios Pharma possui 1.859 concorrentes concorrentes Pfizer (Estados Unidos), Johnson & Johnson (Estados Unidos) e Sanofi (França).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Artios Pharma
- Artios Pharma Bolsters Board of Directors with Appointment of Chris Liu, PhD - Artios Pharma
- Artios Pharma Strengthens Financial Leadership with Appointment of Christine Silverstein as Chief Financial Officer - Artios Pharma
- Artios Presents Positive Initial Phase 1/1b Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023 - Artios Pharma
- Press release Archives - Page 4 of 4 - Artios Pharma
- Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023 - Artios Pharma
- IUCT-Oncopole & Artios join forces to overcome resistance to therapies for familial breast cancer - Artios Pharma
- Artios Announces Initiation of Phase 2 Randomized Trial for ATR Inhibitor ART0380 plus Gemcitabine in Patients with Platinum Resistant Ovarian Cancer - Artios Pharma
- Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer - Artios Pharma
- Artios Appoints Samantha Truex to Board of Directors - Artios Pharma
- More exciting press coverage following $153 Million financing – Series C | Artios
- View more press releases Close
Redes sociais sobre Artios Pharma
- Artios Pharma na Wikipedia, Google News e Yahoo Finance
- Artios Pharma na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Niall Martin 
Ligue para a Artios Pharma em +44 122...
